Amylyx Pharmaceuticals, Inc. (AMLX) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Overview
As of June 12, 2026, Amylyx Pharmaceuticals, Inc. (AMLX) reported trailing twelve-month net income of -$150M, reflecting +65.5% year-over-year growth. The company earned $-1.36 per diluted share over the past four quarters.
Looking at the long-term picture, AMLX's historical earnings data spans multiple years. The company achieved its highest annual net income of $49M in fiscal 2023.
Amylyx Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IONS (-$327M net income, -40.4% margin), BIIB ($1.37B net income, 13.2% margin), MDGL (-$309M net income, -30.1% margin), AMLX has comparable earnings metrics. Compare AMLX vs IONS →
AMLX Earnings vs Peers
Earnings metrics vs comparable public companies
AMLX Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$145M | +52.0% | -$153M | $-1.53 | - | - |
| 2024 | -$302M | -712.4% | -$315M | $-4.43 | -345.4% | -360.2% |
| 2023 | $49M | +124.8% | $39M | $0.70 | 12.9% | 10.2% |
| 2022 | -$198M | -125.6% | -$201M | $-2.98 | -892.4% | -905.7% |
| 2021 | -$88M | -108.0% | -$83M | $-1.52 | - | - |
| 2020 | -$42M | -185.4% | -$39M | $-0.79 | -6504.6% | -6000.8% |
| 2019 | -$15M | - | -$14M | $-0.26 | -1039.0% | -950.5% |
Download Data
Export AMLX earnings history in CSV or JSON format
Free sign-in required to download data
What if you invested $1,000 in AMLX back in 2019?
Total return with dividends reinvested · 7+ years of data
Calculate ReturnsHow much would $100/month in AMLX be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs AMLX Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationAMLX vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowAMLX — Frequently Asked Questions
Quick answers to the most common questions about buying AMLX stock.
What is AMLX earnings per share (EPS)?
AMLX trailing twelve-month (TTM) diluted EPS is $-1.36, reflecting +65.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Amylyx Pharmaceuticals, Inc.'s net income?
Amylyx Pharmaceuticals, Inc. (AMLX) trailing twelve-month net income is $-150M as of 2025. Earnings grew +65.5% year-over-year.
Is AMLX profitable?
AMLX is not currently profitable on a TTM basis, reporting a net loss of $-150M. Net margin is N/A. Investors should monitor for a return to profitability.
What is AMLX's earnings growth rate?
AMLX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are AMLX's profit margins?
Amylyx Pharmaceuticals, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -61.6%.
Is AMLX growing earnings?
Yes, AMLX earnings are accelerating — EPS growth of +65.5% exceeds the 5-year CAGR of N/A. TTM net income reached $-150M. Earnings momentum is strengthening.
What was AMLX's best earnings year?
Amylyx Pharmaceuticals, Inc.'s highest annual net income on record is $49M, achieved in fiscal year 2023. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were AMLX's earnings last quarter?
AMLX's most recent reported quarter was Q1 2026. Net income was $-41M with diluted EPS of $-0.37. For a full breakdown of all quarters, see the quarterly earnings table on this page.